Free Trial
→ Massive Data Leak Exposes 512,000-Line Code That Could Change Society Forever (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:IMNM

Immunome Q4 2025 Earnings Report

Immunome logo
$22.19 -1.08 (-4.64%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$22.14 -0.05 (-0.20%)
As of 05/7/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Immunome EPS Results

Actual EPS
-$0.75
Consensus EPS
-$0.65
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A

Immunome Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.79 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immunome Announcement Details

Quarter
Q4 2025
Date
3/3/2026
Time
Before Market Opens
Conference Call Date
Tuesday, March 3, 2026
Conference Call Time
3:00PM ET

Upcoming Earnings

Immunome's Q1 2026 earnings is estimated for Monday, May 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, May 15, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Immunome's Q4 2025 Press ReleasePress Release
(8-K)
Immunome's Q4 2025 Annual reportAnnual report
(10-K)

Immunome Earnings Headlines

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 5 at 4:00 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20260505490944/en/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4/
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
April 29, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260429083050/en/Immunome-Announces-Submission-of-New-Drug-Application-to-U.S.-FDA-for-Varegacestat-for-the-Treatment-of-Adults-with-Desmoid-Tumors/
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
 |  American Alternative (Ad)
A Look At Immunome (IMNM) Valuation As Varegacestat Nears ASCO 2026 Spotlight And FDA NDA Filing
April 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/look-immunome-imnm-valuation-varegacestat-110409343.html
Immunome (IMNM) Receives a Buy from LifeSci Capital
April 20, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IMNM/pressreleases/1195553/immunome-imnm-receives-a-buy-from-lifesci-capital/
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC), Immunome (IMNM) and Eli Lilly & Co (LLY)
April 18, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/LLY/pressreleases/1382575/analysts-offer-insights-on-healthcare-companies-ge-healthcare-technologies-inc-gehc-immunome-imnm-and-eli-lilly-co-lly/
See More Immunome Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email.

About Immunome

Immunome (NASDAQ:IMNM) is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens. In parallel, Immunome is advancing additional candidates in solid tumors, including antibody–drug conjugates and immunomodulatory antibodies that aim to stimulate anti-tumor immune responses. Beyond oncology, the platform has been applied to infectious disease programs, where candidate antibodies against emerging viral threats have been identified and optimized for potential therapeutic or prophylactic use.

Founded in the early 2000s and headquartered in Ann Arbor, Michigan, Immunome has grown from a privately held research operation into a publicly traded company listed on the Nasdaq exchange under the ticker “IMNM.” In 2021, the company completed its initial public offering, providing capital to support ongoing clinical development and platform expansion. Led by President and Chief Executive Officer Greg Bailey, Immunome maintains collaborations with academic institutions and industry partners to advance its pipeline and explore new therapeutic applications of its discovery platform.

View Immunome Profile
Earnings Tools